Executive Moves | Healthcare | BioTuesdays by Kilmer Lucas IR

Executive Moves

Stereotaxis names Kimberly Peery as CFO

Stereotaxis (NYSE American:STXS) appointed Kimberly Peery as CFO, effective October 1, replacing Martin Stammer, who has accepted a position as CFO of a large professional services firm in the St. Louis area. He will...

September 18, 2019

Executive Moves

Salarius Pharma names Scott Jordan as CBO; Mark Rosenblum as EVP finance and interim CFO

Salarius Pharmaceuticals (NASDAQ:SLRX) has appointed Scott Jordan as chief business officer (CBO) and Mark Rosenblum as EVP finance and interim CFO. Mr. Jordan has been Salarius’ CFO since 2016. As CBO, he will lead...

September 13, 2019

Executive Moves

Adamas Pharma names Neil McFarlane as CEO

Adamas Pharmaceuticals (NASDAQ:ADMS) has appointed Neil McFarlane as CEO and a member of its board, effective Sept. 16. Gregory Went, Adamas’ founder, chairman and CEO, will transition to a strategic advisory role...

September 13, 2019

Executive Moves

Gritstone Oncology adds biotech veteran, Elaine Jones, to board

Gritstone Oncology (NASDAQ:GRTS) appointed Elaine Jones as a director, replacing Peter Svennilson, founder of the Column Group and co-lead Series A investor in Gritstone. Dr. Jones was most recently VP, worldwide...

September 12, 2019

Executive Moves

Spartan Bioscience boosts executive team

Closely-held Spartan Bioscience named Blaine Fitzgerald, former VP of finance for Shopify, as CFO. In addition, the company appointed Steve Edgett as EVP to lead its international business development and strategic...

September 5, 2019

Executive Moves

Zegbeh Jallah joins Roth heath care research team

Roth Capital Partners named Zegbeh Jallah as a director and research analyst covering biotechnology. Her research coverage is expected to include SMID cap biotech companies across the therapeutic space, with an initial...

August 27, 2019

Executive Moves

Axsome Therapeutics names David Marek as CCO

Axsome Therapeutics (NASDAQ:AXSM) has appointed David Marek as chief commercial officer, effective Aug. 31. Mr. Marek joins Axsome from Amgen (NASDAQ:AMGN), where he was most recently VP and general manager of the...

August 20, 2019

Executive Moves

Profound Medical names senior finance executive, Steve Forte, to board

Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee. Most recently, Mr. Forte was CFO of Clementia Pharmaceuticals...

August 15, 2019

Executive Moves

Strongbridge Biopharma reports key leadership appointments

Strongbridge Biopharma (NASDAQ:SBBP) named Richard Kollender as COO, promoted Robert Lutz to CFO and appointed David Gill to its board, effective Sept. 3. “Continuing to assemble an experienced, multi-talented executive...

August 14, 2019

Executive Moves

BriaCell Therapeutics names Richard Berman to board

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed Richard Berman to its board of directors. Mr. Berman has more than 35 years of experience in venture capital; senior management; and mergers and acquisitions. He...

August 13, 2019

Stereotaxis names Kimberly Peery as CFO

Salarius Pharma names Scott Jordan as CBO; Mark Rosenblum as EVP finance and interim CFO

Adamas Pharma names Neil McFarlane as CEO

Gritstone Oncology adds biotech veteran, Elaine Jones, to board

Spartan Bioscience boosts executive team

Zegbeh Jallah joins Roth heath care research team

Axsome Therapeutics names David Marek as CCO

Profound Medical names senior finance executive, Steve Forte, to board

Strongbridge Biopharma reports key leadership appointments

BriaCell Therapeutics names Richard Berman to board

Follow Us

Subscribe

General

More

Subscribe